Status:

COMPLETED

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

Lead Sponsor:

Warner Chilcott

Collaborating Sponsors:

Sanofi

Conditions:

Healthy

Eligibility:

FEMALE

40-70 years

Phase:

PHASE1

Brief Summary

Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (prec...

Eligibility Criteria

Inclusion

  • female, 40 to 70 years of age
  • non-lactating and either surgically sterile or postmenopausal
  • body mass index less than or equal to 32 kg/m2 at screening

Exclusion

  • no use of a bisphosphonate within 1 month
  • no history of GI disease
  • no use of any medications within 7-14 days prior to scheduled dosing day

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2009

Estimated Enrollment :

101 Patients enrolled

Trial Details

Trial ID

NCT00868907

Start Date

March 1 2009

End Date

April 1 2009

Last Update

October 12 2011

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Research Site

Gainesville, Florida, United States, 32601

2

Research Site

Miami, Florida, United States, 33126

3

Research Site

Honolulu, Hawaii, United States, 96821

4

Research Site

Evansville, Indiana, United States, 47711

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food | DecenTrialz